
TELA Stock Forecast & Price Target
TELA Analyst Ratings
Bulls say
TELA Bio Inc. is experiencing notable growth, with OviTex unit sales increasing by 20% for the quarter, supported by new customer acquisitions and the successful launch of larger-sized OviTex PRS products. The company reported a gross margin of 65.9%, reflecting an improvement of 230 basis points, which indicates healthy profitability amid ongoing investments in its product portfolio and sales force. Additionally, TELA's financial position has been strengthened by recent equity raises and expanded debt capacity, providing a solid cash runway that may enable continued expansion and innovation through 2026 and beyond.
Bears say
TELA Bio has lowered its full-year 2025 revenue guidance to at least 16% growth year-over-year, a significant decrease from the previously projected growth of 23-27%, now implying revenue of at least $80.4 million compared to earlier expectations. Furthermore, the company's growth outlook for fiscal year 2026 has also been reduced from at least 15% to a mere 8%, reflecting ongoing challenges such as sales force dislocation, pressure on average selling prices, and the strategic focus on denser populated territories, potentially sidelining existing coverage areas. Additionally, TELA's recent quarterly sales of $20.9 million fell short of both internal and market consensus estimates, highlighting underlying weaknesses in sales volumes amid seasonal factors and operational adjustments.
This aggregate rating is based on analysts' research of TELA Bio, Inc. and is not a guaranteed prediction by Public.com or investment advice.
TELA Analyst Forecast & Price Prediction
Start investing in TELA
Order type
Buy in
Order amount
Est. shares
0 shares